➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Johnson and Johnson

Last Updated: December 5, 2020

DrugPatentWatch Database Preview

Litigation Details for Bayer Pharma AG v. Watson Laboratories Inc. (D. Del. 2012)

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

Bayer Pharma AG v. Watson Laboratories Inc. (D. Del. 2012)

Docket   Start Trial Date Filed 2012-12-18
Court District Court, D. Delaware Date Terminated
Cause 35:271 Patent Infringement Assigned To Leonard Philip Stark
Jury Demand Defendant Referred To
Patents 6,133,251; 6,884,793; 8,071,577
Attorneys Derek James Fahnestock; Dominick T. Gattuso; Jack B. Blumenfeld
Link to Docket External link to docket
Small Molecule Drugs cited in Bayer Pharma AG v. Watson Laboratories Inc.
The small molecule drug covered by the patents cited in this case is   Start Trial .

Details for Bayer Pharma AG v. Watson Laboratories Inc. (D. Del. 2012)

Date Filed Document No. Description Snippet Link To Document
2012-12-18 1 Delaware, 22. The patent-in-suit is United States Patent No. 8,071,577 (“the ’577 patent”) (attached as …ANDA product. CLAIM FOR PATENT INFRINGEMENT OF UNITED STATES PATENT NO. 8,071,577 27. Plaintiffs incorporate…ACTION l. This is an action for patent infringement arising under the patent laws of the United States, 35…filed their application for this patent on April 15, 2005. The ’577 patent was issued on December 6, 2011…infringes one or more claims of the ’577 patent. 29. The ’577 patent covers Bayer HealthCare’s Natazia® tablets External link to document
2016-07-18 153 had listed U.S. Patent No. 6,133,251 ("the '251 patent") and U.S. Patent No. 6,884,793 (… ' 577 Patent Claims ' 793 Patent Claim 1 Patents) Patents) Phase 1 …United States Patent No. 8,071 ,577 ("the ' 577 patent" or "the patent-in-suit"…329) F. The Patent-in-Suit: U.S. Patent No. 8,071,577 36. The patent-in-suit is the &…#39;s Prior Patents Covering Natazia® 41. The ' 577 patent is the third patent that Bayer External link to document
2016-12-28 165 infringe Bayer's valid U.S. Patent No. 8,071,577 ("the '577 patent"). (See D.I. 153, 154…infringed patent must show that the following factors favor the requested relief: (i) the patent holder …practice of the [patent-in-suit] outside the context of experimentation ... until after the patent's expiration…its patent if "infringing activity" is permitted to occur during the life of the patent. By…16 Page 2 of 8 PageID #: 3760 In this patent litigation brought by Plaintiffs Bayer Pharma AG External link to document
2012-12-18 4 the Commissioner of Patents and Trademarks for Patent/Trademark Number(s) 8,071,577 B2;. (mdb) (Entered…18 December 2012 1:12-cv-01726-LPS Patent Defendant District Court, D. External link to document
2014-03-20 83 that issued to the Dittgen Group as U.S. Patent No. 6,133,251. (D.I. 61, ex. 2 at 2) It was subsequently…double patenting, in light of a prior patent that had been issued to the Dittgen Group, U.S. Patent No. …alleges infringement of U.S. Patent No. 8,071,577 (the "'577 Patent"). Pending before the …divisional of a U.S. patent application, which, in turn, is a continuation of another U.S. patent application…;577 Patent on December 6, 2011, listing Endrikat and Duesterberg as inventors. ('577 Patent at 1 External link to document
2014-09-30 99 alleges infringement of U.S. Patent No. 8,071,577 (the “'577 Patent”).l Presently before the Court…example, U.S. Patent No. 4,621,079 (the “'079 Patent”), cited in the '577 Patent, claims: 1. ….2 (D.I. 8 at 11 6) B. The '577 Patent The '577 Patent is entitled “Multi-Phase Contraceptive…that “[a] claim in a patent provides the metes and bounds of the right which the patent confers on the patentee…“[i]t is a bedrock principle of patent law that the claims of a patent define the invention to which the External link to document
>Date Filed >Document No. >Description >Snippet >Link To Document

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
Harvard Business School

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.